

## Final Agenda

### Virtual healthbook CME Live Tumor Board

## Integrating CAR T-Cell Therapy into Real-World Lymphoma Practice

<b>Organizer:</b>	H+O communications Ltd.
<b>Possible Dates:</b>	June 25, 2026
<b>Duration:</b>	18:00 – 19:40
<b>Chair:</b>	PD Dr Dr Marc Wehri, University Hospital Inselspital Bern
<b>Expert panel:</b>	Prof. Andreas Holbro, University Hospital Basel Dr Guido Ghilardi, Oncology Institute of Southern Switzerland Erik Aerts, University Hospital Zurich Dr Veronika Ballova, Baden Cantonal Hospital Seok-Yun Lee, University Hospital Inselspital Bern

### Program Description

The healthbook CAR T Tumor Board is a high-level, CME-accredited platform dedicated to advancing therapeutic decision-making in relapsed and refractory lymphoma.

Bringing together leading Swiss hematology experts, this interactive, case-driven format addresses a central strategic question in today's rapidly evolving treatment landscape:

How can advanced immunotherapies be optimally positioned within increasingly complex treatment algorithms?

Rather than promoting a single modality, the discussion centers on comparative clinical reasoning, sequencing strategies, and individualized patient selection — reflecting the reality of a therapeutic environment that now includes CAR T-cell therapies, bispecific antibodies, and other emerging immunotherapeutic approaches.

This format offers:

- Visibility among key Swiss hematologists and treatment decision-makers
- Association with a scientifically balanced, forward-looking educational initiative
- Presence within high-level discussions on sequencing and therapeutic positioning
- Extended digital reach through the healthbook platform and post-event amplification

The healthbook Tumor Board serves as a neutral, expert-led forum where advanced therapies are discussed in context — contributing to how innovation is thoughtfully integrated into real-world clinical practice.

## Final Agenda

18:00 – 18:05	<b>Welcome &amp; Introduction</b> Chair: PD Dr Dr Marc Wehrli	5 min
18:05 – 18:35	<b>Case 1: Early Relapse — Optimal Timing for CAR T-Cell Referral</b> Prof. Andreas Holbro & Dr Veronika Ballova <i>Presentation: 20 min &amp; Discussion: 10 min</i>	
18:35 – 18:55	<b>Case 2: When and How to Bridge — Sequencing CAR T in Real-World Practice</b> Dr Guido Ghilardi <i>Presentation: 10 min &amp; Discussion: 10 min</i>	
18:55 – 19:15	<b>Case 3: High-Risk and Frail Elderly Patients — Navigating Complex Treatment Decisions</b> Erik Aerts <i>Presentation: 10 min &amp; Discussion: 10 min</i>	
19:15 – 19:35	<b>Case 4: Relapsed Primary CNS Lymphoma – Evaluating CAR T-Cell Therapy in a High-Risk Setting</b> Seok-Yun Lee <i>Presentation: 10 min &amp; Discussion: 10 min</i>	
19:35 – 19:40	<b>Conclusion</b> Chair: PD Dr Dr Marc Wehrli	5 min